Is the Oncotype DX assay covered by health insurance?
Genomic Health is pleased that many payers representing more than 200 million lives covered have established favorable coverage policies for the Oncotype DX assay for node-negative, estrogen-receptor-positive patients. It is unknown at this time whether payers will cover the Oncotype DX assay for patients with node-positive breast cancer. Through our Genomic Access Program (GAP), authorized healthcare providers can request that a benefits investigation be performed for a patient to provide her with information about her specific coverage and potential financial responsibility. Click here for more information about insurance coverage and reimbursement.
